The FDA on July 30, 2020 approved TECENTRIQ® (Atezolizumab) in combination with COTELLIC® (Cobimetinib) and ZELBORAF® (Vemurafenib) for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. TECENTRIQ® along with COTELLIC® and ZELBORAF® are products of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
